Barry MJ, Edgman-Levitan S Shared decision making--pinnacle of patient-centered care. N Engl J Med. 2012 Mar 1;366(9):780-1. doi: 10.1056/NEJMp1109283. No abstract available.
Commodore-Mensah Y, Samuel LJ, Dennison-Himmelfarb CR, Agyemang C Hypertension and overweight/obesity in Ghanaians and Nigerians living in West Africa and industrialized countries: a systematic review. J Hypertens. 2014 Mar;32(3):464-72. doi: 10.1097/HJH.0000000000000061.
Demiris G, Speedie S, Finkelstein S A questionnaire for the assessment of patients' impressions of the risks and benefits of home telecare. J Telemed Telecare. 2000;6(5):278-84. doi: 10.1258/1357633001935914.
Glasgow RE, McKay HG, Piette JD, Reynolds KD The RE-AIM framework for evaluating interventions: what can it tell us about approaches to chronic illness management? Patient Educ Couns. 2001 Aug;44(2):119-27. doi: 10.1016/s0738-3991(00)00186-5.
Kretchy IA, Owusu-Daaku FT, Danquah S Locus of control and anti-hypertensive medication adherence in Ghana. Pan Afr Med J. 2014 Jan 18;17 Suppl 1(Suppl 1):13. doi: 10.11694/pamj.supp.2014.17.1.3433. eCollection 2014.
Sanuade OA, Awuah RB, Kushitor M Hypertension awareness, treatment and control in Ghana: a cross-sectional study. Ethn Health. 2020 Jul;25(5):702-716. doi: 10.1080/13557858.2018.1439898. Epub 2018 Feb 15.
Staessen JA, Wang JG, Thijs L Cardiovascular protection and blood pressure reduction: a meta-analysis. Lancet. 2001 Oct 20;358(9290):1305-15. doi: 10.1016/S0140-6736(01)06411-X. Erratum In: Lancet 2002 Jan 26;359(9303):360.
Stephenson J Noncompliance may cause half of antihypertensive drug "failures". JAMA. 1999 Jul 28;282(4):313-4. doi: 10.1001/jama.282.4.313. No abstract available.
Addressing Hypertension Control in Africa (ADHINCRA) Study
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.